Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: January 27, 2023

Details for Patent: 7,056,916

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,056,916
Title:Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract: A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1 C.sub.4-alkyl, halogen, OH, or --O--C.sub.1 C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1 C.sub.4-alkyl, halogen, OH, or --O--C.sub.1 C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1 C.sub.4-alkyl, OH, halogen, --O--C.sub.1 C.sub.4-alkyl, --O--C.sub.1 C.sub.4-alkylene-COOH, or --O--C.sub.1 C.sub.4-alkylene-CO--O--C.sub.1 C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s): Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim am Rhein, DE), Schollenberger; Hermann (Ingelheim am Rhein, DE), Pestel; Sabine (Biberach, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Mietingen, DE), Buettner; Frank (Ummendorf, DE), Heine; Claudia (Biberach, DE), Lustenberger; Philipp (Warthausen, DE), Hoenke; Christoph (Ingelheim, DE), Rudolf; Klaus (Warthausen, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/705,012
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Delivery;

Drugs Protected by US Patent 7,056,916

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim STIOLTO RESPIMAT olodaterol hydrochloride; tiotropium bromide SPRAY, METERED;INHALATION 206756-001 May 21, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,056,916

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 53 282Nov 15, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.